LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Sebia Presents Innovative Solutions for Screening and Diagnostics

By LabMedica International staff writers
Posted on 22 May 2023
Print article
Image: The new fully automated Alegria 2 instrument (Photo courtesy of Sebia)
Image: The new fully automated Alegria 2 instrument (Photo courtesy of Sebia)

Sebia (Lisses, France) is showcasing its innovative solutions for screening and diagnostics in oncology, metabolic diseases, genetic disorders and autoimmune diseases at WorldLab–EuroMedLab Roma 2023.

At EuroMedLab Rome 2023, Sebia is highlighting the new Alegria 2 instrument, a fully automated, sample-to-result solution. The instrument utilizes ORGENTEC’s unique and comprehensive Alegria Monotest portfolio, boasting over 100 parameters. A key distinguishing feature of the Alegria system is its flexibility to run any test from the wide ORGENTEC portfolio at any given time. Physicians can request tailor-made biomarker profiles to be analyzed for individual patients, ensuring the best possible patient care.

Sebia is presenting its CAPILLARYS 3 range of capillary electrophoresis (CE) instruments, designed for complete automation, rapid protein separation, and high resolution. The Sebia CE instruments are equipped with several parallel capillaries, enabling multiple analyses to be carried out simultaneously, offering scalable throughput. The Sebia CAPILLARYS instruments are currently the most widely used CE systems in clinical labs globally. Alongside its CE capabilities, Sebia is highlighting its gel technique-based solutions. These are implemented on the HYDRASYS instruments to separate hemoglobins and detect major hemoglobin variants via electrophoresis on alkaline agarose gels.

Leveraging its extensive experience in CE technology, Sebia has also adapted it for HbA1c testing, which is being showcased at WorldLab–EuroMedLab Roma 2023. This cutting-edge technology offers labs and clinicians accurate and significant results, enhancing patient management. The clear and precise separation of different hemoglobin fractions enables accurate HbA1c measurement due to the high-resolution separation capabilities of the capillary instruments. Given Sebia’s wide offering of capillary instruments, laboratories have the freedom to choose the platform that best suits their needs, ranging from a benchtop standalone instrument to the TLA configuration.

Related Links:
Sebia

Gold Member
Veterinary Hematology Analyzer
Exigo H400
Verification Panels for Assay Development & QC
Seroconversion Panels
New
High Performance Centrifuge
CO336/336R
New
Respiratory QC Panel
Assayed Respiratory Control Panel

Print article

Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Sekisui Diagnostics UK Ltd.